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Abstract Human immunodeficiency virus (HIV)-associated
neurocognitive disorder (HAND) is present in 30–60 % of
HIV-positive (HIV+) individuals and can be assessed by
neuropsychological testing and level of functional impair-
ment. HAND diagnosis therefore requires accurate assess-
ment of functional impairment. The Computer Assessment
of Mild Cognitive Impairment (CAMCI) is a computer-
based screening tool that includes performance-based mea-
sures of functional impairment. We sought to evaluate the
CAMCI as a functional assessment tool in HAND. One hun-
dred fourteen HIV+ patients and 38 HIV-negative (HIV−)
patients underwent neuropsychological and CAMCI testing.
Cognitive status for HIV+ subjects was classified using the
Frascati criteria. HIV+ subjects grouped together and classi-
fied by cognitive impairment performed worse than HIV−
subjects on several of the CAMCI tasks, including following
directions to the supermarket (p =0.05, p =0.03), recalling
which items to purchase (p =0.01, p =0.02), and remembering
to stop at a supermarket (p <0.01, p =0.01) and the post office
(p <0.01, p =0.03). After controlling for hepatitis C status and
depression symptomatology, the tasks “following directions to
the supermarket” and the “recalling which items to purchase”
were no longer significant. The “remembering to run two
separate errands” tasks retained their significance (p <0.01
for both tasks). A subset of the CAMCI tasks therefore suc-
cessfully differentiated HIV+ patients from HIV− individuals.
Differences in hepatitis C status and depression symptomatol-
ogy could account for some of the function assessment differ-
ences in the CAMCI. These results suggest the CAMCI could
be a useful objective performance-based functional assess-
ment in patients with HIV.
Keywords HIV dementia [34] . Assessment of cognitive
disorders/dementia [38] . HIV [144] . Neuropsychological
assessment [205]
Introduction
With the advent of combined antiretroviral therapy (cART) in
the mid-1990s, life expectancy of patients with human immu-
nodeficiency virus (HIV) has improved, including among
those with cognitive impairment. While the phenotype is
milder, the prevalence of HIV-associated neurocognitive dis-
orders (HAND) has remained remarkably high and HAND is
estimated to occur in 30–60 % of HIV-positive (HIV+) indi-
viduals (Grant 2008). HAND includes a wide spectrum of
cognitive impairment ranging from a mild, asymptomatic
form to those who have severe difficulties with everyday
function (McArthur et al. 2010). The disease course is also
variable with patients' cognition worsening over time, stabi-
lizing, or even improving, often depending on compliance
with cART and possibly on the degree of penetration of the
cART across the blood–brain barrier.
Patients with HAND have impairments in everyday func-
tioning. They have increased dependence with instrumental
activities of daily living (IADL) (Heaton et al. 2004), are more
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likely to be unemployed (van Gorp et al. 1999; Benedict et al.
2000), and are more likely to have impaired driving (Marcotte
et al. 1999, 2004). They also have lowermedication adherence
(Hinkin et al. 2002; Andrade et al. 2005), increasing an
individual patient's risk for adverse virologic and clinical
outcomes (Gifford et al. 2000). Finally, patients with all stages
of HAND have an increased mortality risk (Ellis et al. 1997;
Power et al. 2009).
The Frascati criteria for diagnosing HAND combines func-
tional and neurocognitive assessments and stratifies individ-
uals into three categories: (1) Patients with asymptomatic
neurocognitive impairment (ANI) exhibit impairment on neu-
ropsychological testing in at least two cognitive domains but
do not have functional difficulties; (2) Those with mild
neurocognitive disorder (MND) also have impairment on
neuropsychological testing in at least two domains but dem-
onstrate mild functional difficulties; and (3) Patients with
HIV-associated dementia (HAD) exhibit marked impairment
on neuropsychological testing and functional impairment that
interferes with day-to-day activities (Antinori et al. 2007).
Diagnosing a patient with HAND therefore requires an accu-
rate assessment of their functional abilities. Current functional
assessments are based principally on self-report or are too time
consuming to administer in a research or clinical setting.
The Computer Assessment of Mild Cognitive Impairment
(CAMCI)1 was designed and validated to test mild cognitive
impairment in older, HIV-negative (HIV−) patients (Saxton
et al. 2009) and has been modified for use in an HIV+
population. Becker et al. (2011) demonstrated that the
CAMCI is sensitive to mild forms of cognitive impairment
in an HIV+ population.
This investigation sought to determine if the CAMCI could
be used to assess functional impairment in an HIV+ popula-
tion, thereby allowing its use to diagnose HAND and differ-
entiate cognitive status among HIV+ individuals. We hypoth-
esized that subjects with HAND will perform worse on
CAMCI neuropsychological and functional tests compared
with HIV− control subjects and that subjects with HAD will
perform worse than those with ANI and MND.
Methods
Standard protocol approvals, registrations, and patient
consents This study was reviewed and approved by the insti-
tutional review board at Johns Hopkins University. Written
informed consent was obtained from all patients participating
in the study.
Participants One hundred fourteen HIV+ individuals and 38
HIV− individuals were seen at the General Clinical Research
Clinic at Johns Hopkins Hospital in Baltimore, Maryland
from 2007 to 2008. HIV+ patients were recruited from the
Infectious Disease (Moore) Clinic for HIV care at Johns
Hopkins Hospital. We also identified prospective participants
through our other clinical research studies at Johns Hopkins,
specifically the Northeast AIDS Dementia cohort (McArthur
et al. 2004) and the Oxidative Stress Cohort (Mohamed et al.
2010). Demographically matched HIV− individuals were
recruited from inner city Baltimore via flier distributed
throughout Johns Hopkins Hospital. In addition, we asked
our HIV+ participants if they knew family or friends who
were HIV− who would consider participating in the investiga-
tion, thus explaining the overall low education level and high
frequency of drug abuse. Inclusion criteria were the following:
adults 18 years or older, ability to provide written informed
consent, and ability to ambulate at first clinic visit. Exclusion
criteria were the following: history or current opportunistic
central nervous system infection, history or current schizo-
phrenia, current severe affective disorder believed to explain
a subject's cognitive impairment, history of a chronic neuro-
logical disorder including multiple sclerosis and epilepsy, and
current intoxication on illegal drugs or alcohol. Using these
exclusion criteria, a small number of cases were excluded.
All participants underwent a clinical assessment in which
basic demographic data were obtained as well as a complete
medical, psychiatric, and neurologic history. Substance abuse
information was ascertained using a self-assessment question-
naire (Valcour et al. 2004). Alcohol binges were defined as
five or more drinks within 2–4 h. A neurologic examination
was also performed on the HIV+ individuals. Laboratory
testing confirmed HIV serostatus. Hepatitis C status was
confirmed with laboratory testing for HIV+ individuals and
by self-report for HIV− individuals. Laboratory testing for the
HIV+ individuals also included CD4 T cell counts and HIV
RNA levels in the serum. Urine toxicology was performed at
the time of the visit to determine acute intoxication. Seventy-
eight HIV+ subjects also underwent a lumbar puncture and
subsequent testing of CD4 T cell counts and HIV RNA levels
in the cerebrospinal fluid (CSF). Depression symptomatology
was tested using the Beck Depression Inventory (Beck and
Beamesderfer 1974) and a score greater than 16 was defined
as depression. The North American Reading Test was also
administered as a measure of premorbid intellectual abilities.
Classification of cognitive status Neuropsychological testing
was also performed on all subjects. Tests included semantic
and verbal fluency tests (McCarthy and Warrington 1990),
Timed Gait test (Robertson et al. 2006), Grooved Pegboard
1 Since the conclusion of this study, the product name for CAMCI has
been modified to “Computer Assessment of Memory and Cognitive
Impairment” to reflect the broad nature of the impairment identified by
CAMCI and to stress the importance of the identification of potentially
remedial causes.
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test (Klove 1963), Trail Making tests A and B (Reitan and
Wolfson 1985), Digit Symbol Substitution test (Wechsler
1981), the Rey Auditory Verbal Learning test (Rey 1941),
the Computerized Reaction time portion of the California
Computerized Assessment Package (CALCAP) (Miller et al.
1991), the Odd Man Out test (Flowers and Robertson 1985),
and the WAIS III Letter–Number Sequencing test (Wechsler
1997). To assess functional status, we completed the
Karnofsky functional performance scale for each subject
(Karnofsky et al. 1948) and the Function/Quality of Life scale
(Stewart and Ware 1993). Based on these neuropsychological
and functional tests, HIV+ subjects were classified into
HAND category using the Frascati criteria.
CAMCI testing The CAMCI collects data in a standardized
fashion on a Tablet PC. The testing takes approximately
25 min and score reports are available immediately. The
CAMCI has been validated for detection of mild cognitive
impairment among non-demented, community-dwelling
adults 60 years and older with a sensitivity of 86 % and a
specificity of 94 % when compared to adjudication diagnosis
based on paper and pencil tests (Saxton et al. 2009). The
CAMCI utilized in our study was modified for use in an
HIV population. Items removed from the original CAMCI
included many of the items that were not scored but rather
included to provide additional information to the clinician.
Specifically, the removed items include a few of the orienta-
tion questions, the self-reported questions regarding depres-
sion, anxiety, and alcohol use, and the individual perception of
memory questions. The verbal recognition neuropsychiatric
test was also removed. Items added to the original CAMCI
included more trials in the Simple Reaction Time task and the
Digit Span Forward and Reverse tasks.
The modified version of the CAMCI administered to each
subject consisted of seven neuropsychological tests and six
functional tasks. At the beginning of the CAMCI administra-
tion, research staff type in the participants demographic infor-
mation and start the testing. The approximately 25-min pro-
gram then runs independently with the participant interacting
with the computer with a stylus. The computer asks the par-
ticipant the date and then begins with self-report questions
involving previous computer use and driving. The neuropsy-
chological tests then begin. Directions come up on the screen
and are spoken aloud for each test. The tasks include Simple
Reaction Time, Recurring Picture, Go/No Go rule 1 and rule 2,
Word Recall, and Digit Span Forward and Digit Span Reverse.
Together, these tasks assess attention, executive function, dif-
ferent forms of learning and memory, and speed of processing.
The functional task consists of a simulated supermarket–
shopping trip and includes following directions to the super-
market (Shopping Trip Directions task) (Video 1), remember-
ing four items to purchase at the market (Shopping List task),
and subjects are told that they must remember to stop at the
bank (Errand—bank) and post office (Errand—post office)
(Video 2) on their way to the supermarket. When the task
begins, the image on the screen indicates that they are in a
residential neighborhood as seen in first person through the
windshield of a car on the road. Written directions to the
supermarket are located on the bottom right hand corner of
the screen. While driving, they pass a few other cars as well as
people on bikes. While following the directions, the sign for
the bank will come into view on the left hand side of the road
and the subject needs to touch the stylus to the sign in order to
stop at the bank. At the bank, they must perform a transaction
with the automated teller machine (ATM). After leaving the
bank, the post office comes into view on the right hand side of
the road and the subject must remember to touch the stylus to
the post office sign.
Once at the supermarket, the computer presents to the
subject pictures of supermarket items and the subject must
select which items they were supposed to purchase (comple-
tion of the Shopping List task) (Video 3). Following this
assisted recall task, there is an incidental recall task in which
the subject is asked to choose from among other pictures what
other people or objects they noted during the driving task (for
example, the bus that drove past the subject's car).
Statistical analysis Subjects were divided according to their
HIV serostatus, and chi-squared or analysis of variance
(ANOVA) was used to compare performance between HIV−
and HIV+ subjects on the neuropsychological and CAMCI
tests. Comparisons of each neuropsychological and CAMCI
test were also made between HIV− and HIV+ subjects who
were classified into HAND status based on the Frascati
criteria. Again, chi-squared or ANOVAwas used as appropri-
ate. Results were considered significant if the p value was
≤0.05. Sensitivity and specificity of each portion of the
CAMCI was determined, using the Frascati criteria diagnosis
as the gold standard. Regression analysis sought to correlate
CAMCI scores with scores on functional measurements. As
there were some significant differences between the group
demographics, we used a general linear model to fit the
CAMCI test as a function of HIV serostatus, adjusting for
baseline hepatitis C status, depression symptomatology
according to the Beck Depression Inventory, and North Amer-
ican Reading Test (NART) scores. Pairwise comparisons were
made using Tukey's test and Dunnett's T test. Stata 10.0
software (StataCorp LP, College Station, TX) and SAS (SAS
Institute, Cary NC) were used for the statistical analysis.
Results
Participants Table 1 contains the demographic characteristics
of the 38 HIV− subjects and 114 HIV+ subjects. The HIV+
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subjects are shown as a group and also classified into their
HAND diagnosis of normal cognition, ANI,MND, and HAD.
When comparing HIV− to HIV+ subjects, there were no
differences in age, gender, education, race, history of comput-
er use, history of ATM use, or history of driving, thoughHIV+
subjects were less likely to be currently driving (p =0.01). The
groups were also similar in their alcohol and illicit drug use,
with differences noted only in heroin use in the past 6 months
(18 % of the HIV− group versus 6 % of the HIV+ group, p =
0.02). Finally, HIV− and HIV+ subjects had different rates of
hepatitis C infection (27 % of HIV− subjects and 59 % of
HIV+ subjects, p <0.001), depression symptomatology
(mean Beck Depression Inventory score of 5.5 in HIV−
subjects and 10.3 in HIV+ subjects, p <0.00), and NART
scores (mean NART score of 100.2 in HIV− subjects and
95.9 in HIV+ subjects, p =0.02). When comparing HIV−




HIV− NML ANI MND HAD p
value
Total (n) 38 114 38 16 37 22 39
Mean age (SD) 44.3
(10.2)
46.8 (6.4) 0.16 44.3
(10.2)
45.4 (6) 45.9 (6.6) 46.8 (6.4) 48.3 (6.3) 0.22
Education, mean (SD) 12.6 (1.8) 12.7 (2.2) 0.81 12.6 (1.8) 12.3 (1.8) 13.0 (2.8) 12.7 (1.3) 12.6 (2.1) 0.86
Male, no. (%) 26 (68.4) 79 (69.3) 0.92 26 (68.4) 12 (75) 27 (73) 12 (54.6) 28 (71.8) 0.58
Black/African-American/Caribbean,
no. (%)
32 (84.2) 105 (92.1) 0.16 32 (84.2) 13 (81.3) 34 (91.9) 21 (95.5) 37 (94.9) 0.32
Hepatitis C positive, no. (%) 10 (27.0) 67 (58.8) 0.00 10 (27.0) 8 (50) 21 (56.8) 13 (59.1) 25 (64.1) 0.02
Beck Depression Inventory, score
(SD)
5.5 (6.7) 10.25 (9.7) 0.00 5.5 (6.7) 7 (7.1) 9.2 (10) 7.3 (8.4) 14.2 (10) 0.00
NART, mean score (SD) 100.2
(9.7)
95.9 (9.7) 0.02 100.2
(9.7)
98.2 (10.7) 97.0 (11.2) 94.6 (8) 95 (8.8) 0.13
History of computer use, no. (%) 35 (92.1) 97 (85.1) 0.27 35 (92.1) 14 (87.5) 32 (86.5) 20 (90.9) 31 (79.5) 0.54
History of ATM use, no. (%) 37 (97.4) 112 (98.3) 0.74 37 (97.4) 16 (100) 37 (100) 21 (95.5) 38 (97.4) 0.74
History of driving, no. (%) 35 (92.1) 97 (85.1) 0.27 35 (92.1) 13 (81.3) 34 (91.9) 17 (77.3) 33 (84.6) 0.39
Current driving, no. (%) 19 (50.0) 32 (28.1) 0.01 19 (50.0) 5 (31.3) 10 (27) 7 (31.8) 10 (25.6) 0.17
Current alcohol use, no. (%) 7 (18.9) 11 (9.9) 0.13 7 (18.9) 1 (6.3) 3 (8.1) 1 (4.6) 6 (15.4) 0.39
Binge drinking in past 30 days,
no. (%)
5 (13.2) 13 (11.4) 0.77 5 (13.2) 1 (6.3) 6 (16.2) 2 (9.1) 4 (10.3) 0.83
Lifelong history of illicit drug use,
no. (%)
33 (86.8) 101 (88.6) 0.77 33 (86.8) 14 (87.5) 32 (86.5) 20 (90.9) 35 (89.7) 0.98
Lifelong history of cocaine use,
no. (%)
26 (70.3) 85 (74.6) 0.61 26 (70.3) 11 (68.8) 28 (75.7) 19 (86.4) 27 (69.2) 0.6
Lifelong history of heroin use, no.
(%)
19 (51.4) 55 (48.3) 0.74 19 (51.4) 9 (56.3) 14 (37.8) 14 (63.6) 18 (46.2) 0.6
Illicit drug use in previous 30 days,
no. (%)
10 (26.3) 17 (15) 0.11 10 (26.3) 2 (12.5) 5 (13.9) 3 (13.6) 7 (18) 0.59
Cocaine use in previous 6 months,
no. (%)
8 (21.1) 16 (14.3) 0.32 8 (21.1) 2 (13.3) 5 (13.5) 1 (4.6) 8 (21) 0.42
Heroin use in previous 6 months,
no. (%)
7 (18.4) 7 (6.2) 0.02 7 (18.4) 1 (6.3) 1 (2.7) 1 (4.6) 4 (10.5) 0.16









Detectable viral load, no. (%) n/a 46 (41.1) n/a n/a 8 (50) 17 (47.2) 8 (36.4) 13 (34.2) 0.62
Plasma viral load in 100's, mean (SD) n/a 33.0 (104.3) n/a n/a 3.4 (39.8) 20.6 (35.2) 22.6 (38.7) 71.0
(183.8)
0.43
CSF viral load tested, no. (%) n/a 78 (68.4) n/a n/a 11 (68.8) 27 (77.1) 16 (72.7) 24 (61.5) 0.55
CSF viral load detected, no. (%) n/a 27 (23.7) n/a n/a 3 (18.8) 11 (31.4) 4 (18.2) 9 (23.1) 0.71
CSF viral load in 100's, mean (SD) n/a 49.7 (12.8) n/a n/a 3 (2) 3.9 (8.1) 1.9 (3.5) 9.1 (20.2) 0.67
Demographic data comparing HIV− to HIV + subjects as a group and classified into HAND diagnosis
NART National Adult Reading Test, SD standard deviation, ATM automatic teller machine, CSF cerebrospinal fluid, NML normal cognition, ANI
asymptomatic neurocognitive impairment, MND minor neurocognitive disorder, HAD HIV-associated dementia
J. Neurovirol. (2013) 19:432–441 435
subjects and the HIV+ subjects classified into their HAND
diagnosis, there were no differences in age, gender, educa-
tion, race, history of computer use, history of ATM use,
history of driving, and current driving rates. The differences
in hepatitis C status (p =0.02) and depression rates remained
(p <0.01). There was no difference in NART scores between
all of the groups (p =0.13).
Subjects who were HIV+ and hepatitis C positive were
older (mean age of 48.2 versus 44.9, p <0.01), had less edu-
cation (12.2 years of school versus 13.4 years of school, p <
0.01), had lower NART scores (93.9 versus 98.8, p <0.01),
were more likely to have depressive symptomatology (31.3
versus 10.6 %, p <0.01), and were more likely to be African-
American (p =0.03). In addition, among subjects who were
HIV+, approximately 4 % of the normal cognition group had
depressive symptomatology whereas approximately 58 % of
those with HAD had depressive symptomatology (p =0.03).
Among the HIV+ patients, the mean CD4 count was 360.4
(standard deviation 206.2) with a mean plasma viral load of
32,987 copies/ml (standard deviation 104,305 copies/ml). The
HIV+ groups, those with normal cognition, ANI, MND, and
HAD, did not differ in CD4 count, HIV viral load in the
plasma, HIV viral load in the CSF, or in the number of
subjects who had obtained complete viral suppression with
undetectable viral loads in the plasma and the CSF. Fewer
total subjects completed lumbar punctures but there were no
differences in the lumbar puncture rate between the HIV+
groups (p =0.55). While there was a trend toward increased
serum viral load among those withmore advancedHAND, the
differences were not significant (p =0.43). In addition, there
was no difference in the antiretroviral central nervous system
penetration effectiveness (CPE index) (Letendre et al. 2008)
comparing all four groups (p =0.88) or in the pairwise
comparisons.
Neuropsychological testing When comparing HIV− subjects
to HIV+ subjects, there were significant differences in tests of
reaction time and executive function (Table 2). Specifically,
HIV− subjects performed better on the CALCAP, Choice
reaction time test (434 versus 471.6 s, p =0.03), and theWAIS




HIV− NML ANI MND HAD p
value
n 38 114 38 12 34 20 29
Grooved Pegboard dominant hand,
mean in seconds (SD)
81.9 (21.9) 83.9 (21.5) 0.63 81.9 (21.9) 67.1 (5.2) 79.9 (14.5) 82.9
(17.3)
96.0 (28.1) <0.01
Grooved Pegboard non-dominant hand,
mean time in seconds (SD)





Trail Making Part A, mean (SD) 30.7 (10.9) 29.5 (9.9) 0.52 30.7 (10.9) 22.6 (5.8) 27.8 (9.2) 29.4
(10.0)
34.2 (10.1) 0.01




84.6 (47.4) 93 (56.8) 103.4
(49.6)
0.40





CALCAP, choice reaction time, mean (SD) 434 (64) 471.6
(91.2)
0.03 434 (64) 412 (40) 470 (75) 447 (47) 494 (86) <0.01

















RAVLT total, mean score (SD) 46.3 (9.3) 47.4 (10.3) 0.56 46.3 (9.3) 52.4 (8.0) 50.8 (9.3) 48.1 (8.8) 41.0 (10.4) <0.01
RAVLT delayed recall score, mean (SD) 8.8 (3.2) 9.0 (3.1) 0.52 8.8 (3.2) 10.2 (2.6) 10.0 (3.1) 9.7 (3.2) 7.7 (3.4) 0.03
RAVLT recognition score, mean (SD) 11.7 (3.5) 13.5 (1.8) 0.03 11.7 (3.5) 14 (1.29) 13.2 (2.3) 13.6 (2.4) 11.5 (2.9) <0.01
Odd Man Out, mean (SD) 35.7 (3.6) 35.6 (4.0) 0.96 35.7 (3.6) 36.9 (2.3) 36 (3.4) 36.3 (2.3) 34.3 (5.4) 0.17
WAIS III Letter–Number Sequence Test,
mean (SD)
10.2 (3.5) 8.9 (3.0) 0.03 10.2 (3.5) 11.1 (4.6) 9.2 (2.3) 9.1 (2.9) 7.6 (2.3) <0.01
FAS verbal fluency, mean (SD) 40.3 (11.9) 39.1 (12.3) 0.61 40.3 (11.9) 49.7
(11.4)
39.9 (12.2) 37.1 (9.7) 35.4 (12.2) 0.01
Finger Tap dominant hand, score (SD) n/a n/a n/a 49.2 (8.2) 49.2 (9.3) 43.7 (7.2) 44.0 (7.6) 0.01
Finger Tap non-dominant, score (SD) n/a n/a n/a 44.8 (8.6) 42.8 (7.2) 41.6 (5.7) 38.9 (7.7) 0.06
Neuropsychological testing comparing HIV− subjects to HIV+ subjects as a group and divided into HAND diagnosis
SD standard deviation, SCFT semantic category fluency test, RAVLT Rey Auditory Verbal Learning Test, WAIS Wechsler Adult Intelligence Scale,
IHDS International HIV dementia scale, HVLT Hopkins Verbal Learning Test, FP false positive, TP true positive, NML normal cognition, ANI
asymptomatic neurocognitive impairment, MND minor neurocognitive disorder, HAD HIV-associated dementia
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III Letter–Number Sequencing Test (10.2 versus 8.9, p =
0.03). In contrast, the Rey Auditory Verbal Learning Test
recognition score was lower among the HIV− subjects (11.7
versus 13.5, p =0.03), though HAD patients had worse per-
formance than HIV+, normal cognition patients (p <0.01).
CAMCI neuropsychological tests Three of the neuropsycho-
logical tests that are part of the modified CAMCI differenti-
ated between HIV− and HIV+ subjects (Table 3). HIV−
subjects performed better than HIV+ subjects on the Forward
Digit span task (score of 7.6 versus 6.8, p =0.02), Backward
Digit span task (score of 6.2 versus 4.7, p <0.01), and Word
Recall task (score of 3.7 versus 2.4, p <0.01). These differ-
ences were no longer significant when controlling for the
demographic differences of hepatitis C infection and Beck
Depression Inventory score. When controlling for the differ-
ences in NART scores, the Forward and Backward digit span,
as well as Word Recall test, retained their significance (p <
0.01 for all three tests).
When comparing HIV− subjects and the HIV+ subjects
classified into HAND stages, the same neuropsychological
tests showed significant differences between the groups. The
ForwardDigit span score was different among the five groups,
averaging 7.6 in HIV− patients compared to only 6.2 in
patients with HAD (p =0.01). Pairwise comparisons indicated
that the differences between the HIV− and HAD subjects, as
well as between the HIV+, normal cognition and HAD sub-
jects, were significant. The Backward Digit span task was also
different between the five groups, following the same gener-
ally downward trend between the HIV− subjects and the HAD
subjects (score of 6.2 versus score of 4.4, p <0.01). Pairwise
comparisons indicated a significant difference between the
HIV− subjects and the MND and HAD subjects and between
the HIV+, normal cognition group and the MND subjects.
Word Recall scores were also different between the five
groups, decreased from 3.7 in HIV− subjects to 2.1 in HAD
subjects (p <0.01). The pairwise comparisons indicated a
significant difference between the HIV− subjects and all four
categories of HIV+ subjects. When the general linear model
controlled for hepatitis C infection rates and depression symp-
tomatology, differences between the five groups for each of
these tests were no longer their significant.
CAMCI functional tasks Four of the functional tasks in the
CAMCI were able to distinguish between HIV− and HIV+
subjects (Table 3). Specifically, HIV− subjects performed
better on the Shopping Trip Directions task (16.2 versus
15.1, p =0.05), Shopping List task (3.7 versus 3.1, p =0.01),
the Errands—bank (79 versus 53 %, p <0.01), and Errands—
post office tasks (79 versus 56 %, p <0.01) (Fig. 1). After
controlling for hepatitis C status and depression symptomatol-
ogy, the Shopping Trip Directions task and the Shopping List
task were no longer significant. The Errands—bank and
Errands—post office tasks retained their significance (p <
0.01 for both tasks).
The same functional tasks were significant when compar-
ing HIV− patients and HIV+ patients classified by HAND
diagnosis. There was a significant difference between the five
groups on the Shopping Trip Directions task (p =0.03) though
there were no differences in the pairwise comparisons. The
Shopping List task score was different between the five
groups, decreasing from HIV− to HIV+ normal cognition to
those with HAD (p =0.02). The pairwise comparisons further
noted a significant difference between the HIV− subjects and
the HAD subjects. Similarly, the subjects' ability to remember
to stop at the bank and post office (Errands—bank and Er-
rands—post office) worsened from HIV− to HAD (bank, p =
0.01; post office, p =0.03) (Fig. 1). The pairwise comparisons
for both these tasks indicated a significant difference between
the HIV− subjects and the HIV+ normal cognition subjects.
Using the general linear model to control for hepatitis C status
and depressive symptomatology when comparing the HIV−
subjects to the HIV+ subjects classified into HAND diagnosis
resulted in a loss of significance for each of these functional
tasks.
Many of the CAMCI functional tasks correlated with con-
ventional measures of functional performance. The Shopping
Trip Directions task positively correlated with the Karnofsky
performance scale (r =0.19, p =0.04), the Columbia Medica-
tionManagement Test (r =0.38, p <0.001), and the San Diego
Finance test (r =0.30, p <0.001). The Shopping List Task
positively correlated with the Karnofsky performance scale
(r =0.27, p <0.001) and the Columbia Medical Management
Test (r =0.23, p =0.03). In addition, both the Errands—bank
and the Errands—post office task positively correlated with
the Karnofsky performance scale (r =0.21, p =0.02; r =0.25,
p =0.01, respectively) and the Columbia Medication Manage-
ment Test (r =0.22, p =0.03; r =0.27, p =0.01, respectively).
The area under the curve analysis indicates that forward
digit span, forward digit span size, and the functional driving
task differentiate between HIV+ individuals with and without
HAD. Each of these tests achieved good sensitivity, but rela-
tively poor specificity. For example, a forward digit span raw
score cutoff of greater than or equal to 6 gives a sensitivity of
63 % and a specificity of 19 %, a forward span size raw score
cutoff of greater than or equal to 5 gives a sensitivity of 80 %
and a specificity of 9 %, and a raw score on the Shopping Trip
Directions task of greater than or equal to 13 gives a sensitivity
of 75 % and a specificity of 18 %.
Discussion
CAMCI is a computer-based screening tool that includes
performance-based measures of functional impairment. Three
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of the CAMCI neuropsychological tests and four of the
CAMCI functional tests differentiated between HIV− and
HIV + subjects. The neuropsychological tasks of Forward
and Backward Digit span, as well as Word Recall, separated
the groups, as did the functional tasks of following directions
to the supermarket (Shopping Directions task), remembering
four items to purchase (Shopping List task), and remembering
to stop at the bank and post office enroute to the supermarket
(Errands—bank and Errands—post office). In many of these
tasks, the HAD subjects had the worst performance. The
CAMCI neuropsychological tests and functional tests also
correlated with traditional measures of functional impairment.
The CAMCI, therefore, could be a useful objective test of
functional performance in HIV+ individuals. We cannot ex-
clude, however, that differences in hepatitis C status, depres-
sion, and NART scores contributed to these findings.
With the exception of the CAMCI, the current gold stan-
dard of functional assessments are limited by being either time
consuming to perform, or by needing to rely on patients' self-
report, or both. For example, the Karnofsky performance
scale, IADL scale of Lawton and Body, and the Katz/ADL
Lawton self-maintenance scale are each assessments that re-
quire time and expertise to administer and are based on self-
report from either the patient or the provider. Schifitto et al.
demonstrated poor correlation between these more self-
reportedmeasures of functional impairment and neuropsycho-
logical outcomes involving HAND (Schifitto et al. 2001).
Other researchers provided objective functional measures
through rigorous laboratory assessments including testing
abilities to shop, cook, vocational skills, and management of
finances and medications (Heaton et al. 1995). While these
objective measures were an improvement over subjective
functional assessments, such large-scale rigorous laboratory
measures could be impractical for both clinical trials and
clinical practice.
The CAMCI is a potential alternative to these more cum-
bersome assessments. We sought to investigate the CAMCI in
the HIV population and to compare CAMCI measures in HIV
− and HIV+ individuals and in HIV+ individuals with and
without HAND, Because there is no biomarker for HAND
that can be used as a gold standard, the gold standard for
HAND in practice is to use a clinical diagnosis combining
neuropsychological test data, functional assessments, and oth-
er clinical assessments. These assessments (excluding the
CAMCI data) were all used to diagnose HAND from the
initiation of the study, so it would not be possible to compare
the accuracy of the CAMCI results to the accuracy of the
standard neuropsychological tests. Future studies with a lim-
ited neuropsychological test battery and functional assess-
ments can be designed from the start to be compared to the
CAMCI results.
The sensitivity and specificity of the Shopping Trip Direc-
tions task compares favorably to a sensitivity and specificity
of 80 and 57 % for the International HIV Dementia Scale
Fig. 1 CAMCI Functional Directions. Four of the CAMCI functional
tasks demonstrated significant differences in performance between HIV−
and HIV+ subjects as well as between HIV− subjects and HIV+ subjects
classified into HAND criteria. NML = normal cognition; ANI = asymp-
tomatic neurocognitive impairment;MND = minor neurocognitive disor-
der; HAD = HIV-associated dementia
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(Sacktor et al. 2005). The sensitivity and specificity of
CAMCI subtests are also comparable to the sensitivity
(71 %) and specificity (46 %) of the Grooved Pegboard non-
dominant hand test, an established test for HIV dementia
(using a cutoff of 1.5 SD below the age- and education-
adjusted mean).
The CAMCI's utility was demonstrated by the correlation
between the CAMCI testing and traditional measures of func-
tional impairment as well as the sensitivity and specificity of
individual tasks. These measures demonstrate that regardless
of hepatitis C status and depression symptomatology the
CAMCI tests both correlate with previously validated mea-
sures and discriminate between HIV− and HIV+ status. In
addition, the CAMCI discriminates between those that are
cognitively intact and those that have HAD in a manner that
is easy to assess (i.e., a brief computer test).
The CAMCI results also indicate that there may be lower
than expected performance in the group that was categorized
as HIV+with normal cognition. The pairwise comparisons are
notable for the significant differences between the HIV−
subjects and the HIV+ normal cognition subjects on the tasks
of Word Recall and remembering to stop at the bank and post
office (Errands—bank and Errands—post office). Further-
more, the HIV+ normal cognition group performed poorly
on these tasks, with scores closer to subjects with HAND. The
HIV+ normal cognition group, therefore, may have subtle
cognitive difficulties that are being picked up by these
CAMCI tasks. Future research looking at the HIV+ normal
cognition group is needed to determine the significance of
these results.
This study is limited by the demographic differences be-
tween the groups. After controlling for hepatitis C status and
depression symptomatology, there were no longer differences
between many of the CAMCI scores of the different groups.
Subjects with hepatitis C, however, were older and less edu-
cated than those without hepatitis C. Older patients and those
with less education have both been shown to have poorer
performance on cognitive testing and have greater rates of
dementia. Therefore, by controlling for hepatitis C serology,
we have factored out a potentially large influence on the
cognitive test results.
Furthermore, the external validity of our study is chal-
lenged by the severity of cognitive disease in our cohort.
Many of our cohort patients were recruited because of their
concerns and complaints regarding their cognitive status.
They therefore do not represent the typical population of
individuals with HAND that one would encounter in clinical
practice. Later assessments can focus on determining standard
scores in a general population and seek to assess the positive
predictive value of the CAMCI in a general HIV+ population.
The CAMCI may be a useful objective measure of func-
tional performance in the HIV+ population. While the results
are limited by the demographic differences, the CAMCI may
be able to assist clinicians in the diagnosis of HAND. This
new tool therefore provides an opportunity for closer clinical
follow-up and the earlier initiation of treatments specific for
HAND.
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